Japan· JP-4291064F1020
カボザンチニブリンゴ酸塩
A cabozantinib product containing カボザンチニブリンゴ酸塩, registered in Japan by 武田薬品工業, on the national reimbursement list. The same ATC class is registered in 12 of our 19 countries.
Checked against MHLW / PMDA (Japan) on
Informational only — not a medical device.
Where it is registered
Cabozantinib is registered in 12 of 19 countries.
Countries holding a registration under ATC L01EX07 (cabozantinib), each read from that country’s own register.
- This record: Japan, from MHLW / PMDA (Japan)
- 7 of them publish a price we can compare per daily dose
Cabozantinib · ATC L01EX07
12 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
Price per daily dose
What a daily dose of cabozantinib costs, country by country.
Normalised to the WHO defined daily dose (60 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Cabozantinib · price per daily dose (60 mg)
USD · FX 28 Sept 2026
- CH Switzerland$570.30
The record
At a glance
MHLW / PMDA (Japan)- Active substance
- カボザンチニブリンゴ酸塩
- Manufacturer
- 武田薬品工業
- Country
- Japan (JP)
- ATC code
- L01EX07
- ATC class
- Cabozantinib
- Defined daily dose
- 60 mg, O
- Reimbursed
- Yes
- Source register
- MHLW / PMDA (Japan)
- Last checked
- September 25, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
544 interactions on record for cabozantinib.
Graded by severity as the source publishes them — 360 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Cabozantinib · interactions on record
544 records
- 360 severe
- 179 moderate
- 5 minor
Most severe, free to view
- PapaverineA03AD01severe
- CisaprideA03FA02severe
- OndansetronA04AA01severe
- GranisetronA04AA02severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Cabozantinib in 10 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United KingdomCabometyx 20mg tabletsIpsen Ltd
- SpainCABOMETYX 20 MG COMPRIMIDOS RECUBIERTOS CON PELICULAIpsen Pharma
- SwedenCABOMETYX 20 mg Filmdragerad tablettIpsen Pharma
- PolandCabometyxIpsen Pharma
- IrelandCABOMETYX 20 mg film-coated tabletsIpsen Pharma
- BelgiumCabometyx 20 mgIpsen Pharma
- FranceCABOMETYX 20 mg, comprimé pelliculéIPSEN PHARMA
- CanadaCABOMETYXIPSEN BIOPHARMACEUTICALS CANADA INC
Authorised across Europe · EMA
The same active substance is authorised in 9 EEA countries. Names it is sold under:
- Czechia · Cabozantinib Teva
- Denmark · Cabozantinib Teva, Hasgobusno
- Spain · Cabozantinib Sun
- Finland · Cabozantinib Ratiopharm
- Croatia · Kabozantinib Teva
- Iceland · Cabometyx, Cometriq
- Italy · Cabozantinib Teva
- Liechtenstein · Cabometyx, Cometriq
- Norway · Cabometyx, Cometriq
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of MHLW / PMDA (Japan). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/51fa79db-7e12-4587-80de-46b613aef237 GET /v1/drugs/51fa79db-7e12-4587-80de-46b613aef237?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"spec": "２０ｍｇ１錠",
"marks": null,
"source": "mhlw",
"remarks": null,
"yj_code": "4291064F1020",
"category": "内用薬",
"price_yen": 8007.6,
"generic_name": "カボザンチニブリンゴ酸塩",
"product_name_jp": null,
"therapeutic_class": "4291",
"transitional_expiry": null
}See everything about cabozantinib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.